136 related articles for article (PubMed ID: 35927939)
1. Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Talarico F; Chakravarty S; Liu YS; Greenshaw AJ; Passos IC; Cao B
Ann Pharmacother; 2023 Apr; 57(4):463-479. PubMed ID: 35927939
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
3. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae.
Hamm BS; Rosenthal LJ
Psychosomatics; 2020; 61(6):597-606. PubMed ID: 32800347
[TBL] [Abstract][Full Text] [Related]
6. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
Nadeem U; Raafey M; Kim G; Treger J; Pytel P; N Husain A; Schulte JJ
Am J Clin Pathol; 2021 May; 155(6):793-801. PubMed ID: 33316045
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
Kumar J; Jain S; Meena J; Yadav A
J Infect Chemother; 2021 Jun; 27(6):882-889. PubMed ID: 33678548
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.
Okada JI; Yoshinaga T; Washio T; Sawada K; Sugiura S; Hisada T
Clin Transl Sci; 2021 May; 14(3):1092-1100. PubMed ID: 33404133
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.
De Luca P; Scarpa A; De Bonis E; Cavaliere M; Viola P; Gioacchini FM; Ralli M; Ettore C; Claudia C
Am J Otolaryngol; 2021; 42(5):102640. PubMed ID: 33780902
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
Shah S; Das S; Jain A; Misra DP; Negi VS
Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database.
Papazisis G; Siafis S; Cepatyte D; Giannis D; Stamoula E; Tzachanis D; Egberts T
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(19):6003-6012. PubMed ID: 34661260
[TBL] [Abstract][Full Text] [Related]
12. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Shah RR
J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.
Garcia MC; Tsang K; Lohit S; Deng J; Schneider T; Matos Silva J; Mbuagbaw L; Holbrook A
Ann Pharmacother; 2024 Jul; 58(7):742-755. PubMed ID: 37881891
[TBL] [Abstract][Full Text] [Related]
16. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
Rodrigo C; Fernando SD; Rajapakse S
Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19.
Ho TC; Wang YH; Chen YL; Tsai WC; Lee CH; Chuang KP; Chen YA; Yuan CH; Ho SY; Yang MH; Tyan YC
Pathogens; 2021 Feb; 10(2):. PubMed ID: 33671315
[TBL] [Abstract][Full Text] [Related]
18. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis.
Liu D; Li X; Zhang Y; Kwong JS; Li L; Zhang Y; Xu C; Li Q; Sun X; Tian H; Li S
Drug Des Devel Ther; 2018; 12():1685-1695. PubMed ID: 29928112
[TBL] [Abstract][Full Text] [Related]
19. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.
Dauner DG; Dauner KN
J Am Pharm Assoc (2003); 2021; 61(3):293-298. PubMed ID: 33546986
[TBL] [Abstract][Full Text] [Related]
20. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
